JPH0429680B2 - - Google Patents

Info

Publication number
JPH0429680B2
JPH0429680B2 JP58044509A JP4450983A JPH0429680B2 JP H0429680 B2 JPH0429680 B2 JP H0429680B2 JP 58044509 A JP58044509 A JP 58044509A JP 4450983 A JP4450983 A JP 4450983A JP H0429680 B2 JPH0429680 B2 JP H0429680B2
Authority
JP
Japan
Prior art keywords
blood coagulation
factor
polyethylene glycol
molecular weight
coagulation factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP58044509A
Other languages
English (en)
Japanese (ja)
Other versions
JPS59172425A (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to JP58044509A priority Critical patent/JPS59172425A/ja
Publication of JPS59172425A publication Critical patent/JPS59172425A/ja
Publication of JPH0429680B2 publication Critical patent/JPH0429680B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP58044509A 1983-03-18 1983-03-18 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤 Granted JPS59172425A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP58044509A JPS59172425A (ja) 1983-03-18 1983-03-18 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58044509A JPS59172425A (ja) 1983-03-18 1983-03-18 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤

Publications (2)

Publication Number Publication Date
JPS59172425A JPS59172425A (ja) 1984-09-29
JPH0429680B2 true JPH0429680B2 (Direct) 1992-05-19

Family

ID=12693520

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58044509A Granted JPS59172425A (ja) 1983-03-18 1983-03-18 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤

Country Status (1)

Country Link
JP (1) JPS59172425A (Direct)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
JP5539607B2 (ja) 2003-02-26 2014-07-02 ウェルズ ファーゴ バンク ナショナル アソシエイション ポリマー−ｖｉｉｉ因子部分結合体
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
AU2004296860B2 (en) * 2003-12-03 2010-04-22 Novo Nordisk A/S Glycopegylated factor IX
AU2014280936B2 (en) * 2004-06-30 2016-12-15 Nektar Therapeutics Polymer-factor ix moiety conjugates
ES2390082T5 (es) * 2004-06-30 2018-01-19 Nektar Therapeutics Conjugados de resto de Factor IX y polímeros
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
CA2585758C (en) 2004-10-29 2017-08-01 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
PL2363414T3 (pl) * 2004-11-12 2022-09-05 Bayer Healthcare Llc Ukierunkowana na miejsce modyfikacja FVIII
KR20070092754A (ko) * 2004-12-27 2007-09-13 백스터 인터내셔널 인코포레이티드 중합체 - 폰 빌레브란트 인자 - 접합체
WO2006074467A2 (en) 2005-01-10 2006-07-13 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
ES2406267T3 (es) 2007-04-03 2013-06-06 Biogenerix Ag Métodos de tratamiento usando G-CSF glicopegilado
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
AU2009219232B2 (en) 2008-02-27 2014-02-27 Novo Nordisk A/S Conjugated Factor VIII molecules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5959629A (ja) * 1982-09-27 1984-04-05 Nippon Chem Res Kk 効力持続性組成物
JPS6042087A (ja) * 1983-08-19 1985-03-06 Nec Corp プリンタ

Also Published As

Publication number Publication date
JPS59172425A (ja) 1984-09-29

Similar Documents

Publication Publication Date Title
JPH0429680B2 (Direct)
CN1165483B (zh) 顺氯氨铂和2,2'-二硫代-二(乙磺酸盐)(二巯乙磺酸钠)的组合物
JPH0525470B2 (Direct)
JPH0534337B2 (Direct)
CN1926155B (zh) 羟乙基淀粉
KR840001798B1 (ko) 서방출성 조성물의 제조방법
JPH01500997A (ja) ヒアルロニダーゼの使用
RU2136291C1 (ru) Полифункциональный кровезаменитель для лечения кровопотери и шока
GB2221907A (en) Superoxide dismutase composition.
JP2003339853A (ja) 安定な透析用剤
JPS6058927A (ja) 放射能標識血小板製剤
AU725441B2 (en) An agent for preventing and/or treating multiple organ failure
JPH02273176A (ja) グリコサミノグリカンで修飾されたスーパーオキシドジスムターゼ及びその製造法
US5439894A (en) Dextrin derivatives for the treatment of acidic conditions
EP1210944A1 (en) Blood plasma replacement solution
POLEC et al. Protective effect of ascorbic acid, isoascorbic acid and mannitol against tetracycline-induced nephrotoxicity
Kyle et al. Evaluation of tryptophan mustard (NSC-62403) in patients with plasmacytic myeloma
US4271150A (en) Urokinase preparation for oral administration
JPH04225923A (ja) エリスロポイエチンの水性医薬製剤及びその使用
JPH0569508B2 (Direct)
JPH0215193B2 (Direct)
JPH02231076A (ja) デキストラン修飾スーパーオキシドジスムターゼ
JPS5995221A (ja) 食細胞機能調節作用を有する医薬組成物
JPH036790B2 (Direct)
JPS59204130A (ja) 新規プラスミノ−ゲンアクチベ−タ誘導体を含有してなる経口投与薬剤